Clinical Trials Logo

Filter by:
NCT ID: NCT02779361 Completed - Healthy Volunteers Clinical Trials

Effect of Tea Consumption on Steroid Profile in Healthy Volunteers

Start date: January 2016
Phase: Phase 1
Study type: Interventional

Open label phase I clinical trial in healthy volunteers designed to assess changes on steroid profile after green tea consumption.

NCT ID: NCT02777970 Completed - Acute Pain Clinical Trials

Tramadol Hydrochloride and Dexketoprofen Trometamol for the Oral Treatment of Moderate to Severe Acute Pain Following Removal of Impacted Lower Third Molar

DAVID
Start date: April 2016
Phase: Phase 4
Study type: Interventional

The study is aimed to evaluate the analgesic efficacy of TRAM.HCl/DKP.TRIS 75mg/25mg oral fixed drug combination in comparison with TRAM.HCl /paracetamol 75mg/650mg in the treatment of moderate to severe acute pain.

NCT ID: NCT02777450 Completed - Low Back Pain Clinical Trials

Validity and Predictive Value of Manual Clinical Test to Identify Symptomatic Segments in Lumbar Chronic Patients

Start date: December 2015
Phase: N/A
Study type: Observational

This study evaluates the predictor value of manual test in lumbar chronic patients blocks. Bibliography has show limited evidence of clinical predictors in lumbar blocks. Prior to lumbar facet block or medial branch denervation patient will be evaluated with manual provocative segmental movements, lumbar sagittal range of motion, manual segmental movement and slump neural test . Immediate, one and six months effect will be registered.

NCT ID: NCT02776735 Completed - Clinical trials for Juvenile Idiopathic Arthritis

An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)

SKYPP
Start date: September 6, 2016
Phase: Phase 2
Study type: Interventional

Primary Objective: To describe the pharmacokinetic (PK) profile of sarilumab in patients aged 2-17 years with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) in order to identify the dose and regimen for adequate treatment of this population Secondary Objective: To describe the pharmacodynamic (PD) profile, the efficacy and the long-term safety of sarilumab in patients with pcJIA.

NCT ID: NCT02776683 Completed - Clinical trials for Colorectal Neoplasms

Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer

INVICTAN®-3
Start date: June 8, 2016
Phase: Phase 3
Study type: Interventional

The objective of this trial is to evaluate the safety and tolerability of BI 695502 in combination with leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) and as maintenance therapy (when applicable). As well as to evaluate the following efficacy parameters: Progression-free survival (PFS), objective response rate (proportion of patients with complete response [CR] plus partial response [PR]), overall survival (OS), duration of response (DOR), time to progression (TTP).

NCT ID: NCT02776267 Completed - Clinical trials for Coronary Heart Disease

Percutaneous Coronary Intervention With the Angiolite Drug-eluting Stent: an Optical Cohenrece Tomography Study

Start date: May 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to perform a first-in-man assessment of feasibility, exploratory efficacy and clinical performance of the novel Angiolite drug-eluting stent (iVascular, Barcelona, Spain) utilizing intracoronary optical coherence tomography (OCT).

NCT ID: NCT02776072 Completed - Multiple Sclerosis Clinical Trials

Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)

EFFECT
Start date: May 2016
Phase: N/A
Study type: Observational

The primary objective of the study is to evaluate the real-world clinical effectiveness, as measured by the proportion of participants relapsed at 12 months, in participants treated with dimethyl fumarate (DMF). Secondary objectives of the study are: To evaluate the real-world clinical effectiveness, as measured by the proportion of participants relapsed at 12 months, in participants treated with DMF, glatiramer acetate (GA), teriflunomide, or fingolimod both in the overall participant cohort and in a subset of participants who were naïve to disease-modifying therapy (DMT) and were diagnosed with multiple sclerosis (MS) within 3 years of starting the index therapy; To compare relapse activity, defined as annualized relapse rate (ARR), among participants treated with DMF, GA, teriflunomide, or fingolimod; To compare MS-related hospitalizations among participants treated with DMF, GA, teriflunomide, or fingolimod; To compare intravenous corticosteroid use among participants treated with DMF, GA, teriflunomide, or fingolimod.

NCT ID: NCT02775903 Completed - Clinical trials for Myelodysplastic Syndromes

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

Start date: June 3, 2016
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of subcutaneous azacitidine in combination with durvalumab as compared with subcutaneous azacitidine alone in adults with previously untreated, higher risk MDS who are not eligible for HSCT or in adults ≥ 65 years old with previously untreated AML who are not eligible for HSCT, with intermediate or poor cytogenetic risk.

NCT ID: NCT02775708 Completed - Clinical trials for Any Gastric Condition Which Requires Capsule Endoscopy

Development of Applications of the ® PillCam Endoscopy System and Evaluation of Their Performance

NOISE
Start date: March 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to support development of PillCam Endoscopy System applications.

NCT ID: NCT02774616 Completed - Heart Failure Clinical Trials

BIO|MASTER.Ilivia Family / Plexa

Start date: June 2016
Phase: N/A
Study type: Interventional

Post-Market Clinical Follow-up of the new Ilivia ICD Family and the new Plexa right ventricular lead to fulfill requirements by the notified body and to support regulatory approval outside of the CE region